StageZero Life Sciences Ltd T.SZLS

Extreme Dissapointement in Botched Launch

[johnny007]

Followed the Aristotle 'launch' and financials.

Aristotle: It is not really a proper launch as expected.
Expected was a launch through a capable 3rd party paying the bills
and getting all the clients (patients) for the tests.

Now what happened?
They buy a clinic for roughly 1/3 of MCAP (3/4 left),
trying to use it for a 'self launch'.

This is like when you are a failed author of your new book
nobody likes to publish and you decide to pay for the press
and distribution yourself. Probably not a very successful launch.

This not enough, financials only add up in more and more costs.
Covid testing wasn't able to produce positive results as they burn
everything through *who knows what* (they call it R&D and management).

Now what do you expect will happen to cash flow,
with the new clinic for 1/3 of mcap?
Only purchased to push Aristotle into the public:
  clinic acquisition costs $15M+
  clinic annual burn rate of ??? (I guess around $5M?)

Company has failed big time and even left analysts speechless
with their 'self launching'.

Company could hardly keep up with the current running costs
without this clinic and only thanks to constant stock offerings.

Last but not least: Aristotle would need proper US FDA
blessing (certification), as only that would lead to proper
reimbursements from insurers.
Same FDA certificate would also allow to roll out Aristotle
to the best and most efficient labs across the US, EU and so forth.

These lab rights they are using won't help them at all,
as it also didn't help them with the other tests.
BTW, some (of not most) of the cancer tests only show sensitivity < 90.

Even the once crooked biotech companies like PolarityTE are now walking
this FDA path (yes no test, but transplant).
Also this animal/human testing company is going the FDA route: VolitionRx.

StageZero's strategy has failed at this point.
Would have been better to invest the 15M shares in an FDA approved
Aristotle test.
They only showed one (old) conference paper: That won't cut it!

The moment I read the NR with the clinic acquisition, I sold.

Best of luck to you.

PS: Yes, I am an old genenews trader and got out alive.
Hope 200dma will hold.
In case they followup with a new offering to cover the new clinic costs
for the next 12 month, I would eye for 50c.

[Jabookie75]

Finally, someone on this board named Johnny who is lucid and can accept reality.  Very nice post.

[tineta]

Sell your shares, I will take all home. 

[johnny007]

"Excellent" reply. If you would have read, I did that days ago at 1.16 which reduced my profit by roughly 11c to the 20dma. At this time I am not planning anything with this company, but will check what their next steps are. By now, they should be aware that market and analysts are not welcoming their 'new strategy'. Not really new, as they ran the same concept with the old

[LithLover]

Hmmmm I don't buy it.  You wait years and leave when we only see the part of a launch. There is more to come regarding emplouers, other partners, info on Care Oncology not to mention Q1. Also Tripp will want something much more positive going into the vote and AGM, there will be additional NRs coming. I would have waited at least another 6 weeks.  You wait years and cant see

[capebretongirl]

I think its safe to assume that Tripp will have something out in the good news department shortly - heaven knows we could use it judging from today's share price action!   Tripp knows this will be needed prior to the vote and that package is aleady in the mail.  As it stands at the moment he would be hard pressed to garner a 40% following............

[Jabookie75]

Just listen to 35:30 of the most recent investor call after JHT drops and our Clarus analyst whispers how disappointed he is.  Disappointed in JHT dropping or disappointed in our Aristotle roll out.  Only he knows for sure.  What I know is that Clarus facilitated the last few rounds of financing and likely aren't guys you want feeling "disappointed".  The extreme

[gojotv!]

Sorry to hear that that package is in the mail, as so many votes will be in the hands of the disgruntled. Which puts non- shareholders in a bind of their own making... After they undermined investor confidence with vague criticism of Tripp, driving the share price down... Do they vote for Tripp, so they can get back in cheap, or against him, and watch the share price soar out of reach...? How do

[Nailbiter1]

This post has been removed in accordance with Community Policy

[johnny007]

Addendum: Clarus Downgrade and FAQ The purchase price giving around 25% dilution hasnt been unseen, also the costs involved handling the new beast. They pointed their fingers on exactly this self deployment, where other insurance companies didn't want to jump in. One of the reasons as I have laid out and Clarus also hinted at is the lack of transparency of Aristotle: - No volumes of papers

[Mykndrsn]

This post has been removed in accordance with Community Policy

[johnny007]

Correct, will do. Yes, I was a bit too emotional, angry that this didn't play out. Best.

[Jabookie75]

This post has been removed in accordance with Community Policy

[Jabookie75]

This post has been removed in accordance with Community Policy

[vicky55]

This post has been removed in accordance with Community Policy

[johnny007]

For some reason, somebody deleted my followup message - 'bad sports' ? Here I redo the message and also like to correct myself, as 15M + 8M shares will be added to 'the deal' buying a new cost center. So not 25% but 38% dilution. Obviously the new operations require funding, hence my next entry (if at all) will depend on the next PP. xxx Addendum: Clarus Downgrade and FAQ The

[johnny007]

And here my findings about the to be acquired company, founded in 2013 in London and having the trade-mark "Care Oncology Clinic". See Which company? How come SZLS did not provide detailed documentation? They should be required to provide all details with pushed forward AGM for SH vote no? Highly highly likely the following entity. It is a distressed micro size UK company with

[johnny007]

Looking around their newly named 'SEEK Group', they are in a 'searching mission'. Interestingly, they dropped the name 'Health Clinics Limited' also having a new address. This probably due to the current asset offloading to SZLS with the Care Oncology Clinic "COC" portion. Lots of question, but whats new with SZLS right? We remember Oncore and all the other '

[johnny007]

Endole's record match 'Health Clinics Limited', also the people running the remaining 'SEEK Group' having 'Care Oncology Clinic UK' in their Portfolio. Yes, that is the one. A foggy construct match in heavens.

[johnny007]

Last one, SEEK Group is spinning off their subs - their new business. So SZLS is buying 1-2 of their spin-outs (they brag about this success). Too bad SEEK Group is private, they make another good business with 23M shares perhaps for some 6 employees and GBP -808k equity (net assets). Not so great for SZLS SH IMHO.

[RelevantStock]

This post has been removed in accordance with Community Policy

[johnny007]

I am the first one here who found the actual target company. I am sure the dear analyst and broker did his job as well, right after the NR. Please feel free to look into my message history, you will see proper DD and also periods of bullishness for this company. Yes, of course, I did mature my viewpoint here. Instead of trying to silent me with your tone, perhaps you could also DD the situation

[Lithlow]

This post has been removed in accordance with Community Policy

[Jabookie75]

This post has been removed in accordance with Community Policy

[Mickey55]

This post has been removed in accordance with Community Policy